CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 113 filers reported holding CRINETICS PHARMACEUTICALS IN in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $86,129,241 | +21.0% | 2,896,074 | -26.7% | 1.83% | +41.9% |
Q2 2023 | $71,193,344 | +12.2% | 3,950,796 | 0.0% | 1.29% | +3.5% |
Q1 2023 | $63,449,784 | +8.5% | 3,950,796 | +23.6% | 1.25% | +11.3% |
Q4 2022 | $58,502,831 | -6.8% | 3,196,876 | 0.0% | 1.12% | -4.0% |
Q3 2022 | $62,787,000 | +5.3% | 3,196,876 | 0.0% | 1.17% | +8.0% |
Q2 2022 | $59,622,000 | -15.0% | 3,196,876 | 0.0% | 1.08% | -5.1% |
Q1 2022 | $70,171,000 | -22.7% | 3,196,876 | 0.0% | 1.14% | -2.6% |
Q4 2021 | $90,823,000 | +44.0% | 3,196,876 | +6.7% | 1.17% | +68.5% |
Q3 2021 | $63,084,000 | +11.7% | 2,996,876 | 0.0% | 0.69% | +21.4% |
Q2 2021 | $56,491,000 | +34.3% | 2,996,876 | +8.8% | 0.57% | +45.3% |
Q1 2021 | $42,075,000 | +8.3% | 2,753,567 | 0.0% | 0.39% | +15.6% |
Q4 2020 | $38,853,000 | -10.0% | 2,753,567 | 0.0% | 0.34% | -37.3% |
Q3 2020 | $43,148,000 | -10.6% | 2,753,567 | 0.0% | 0.54% | -20.2% |
Q2 2020 | $48,242,000 | +60.9% | 2,753,567 | +35.0% | 0.68% | +34.7% |
Q1 2020 | $29,977,000 | -41.4% | 2,039,282 | 0.0% | 0.50% | -31.0% |
Q4 2019 | $51,166,000 | +66.8% | 2,039,282 | 0.0% | 0.73% | +25.4% |
Q3 2019 | $30,671,000 | -39.8% | 2,039,282 | 0.0% | 0.58% | -26.3% |
Q2 2019 | $50,982,000 | +17.0% | 2,039,282 | +6.5% | 0.79% | +17.2% |
Q1 2019 | $43,569,000 | -24.1% | 1,914,282 | 0.0% | 0.67% | -36.5% |
Q4 2018 | $57,409,000 | +4.7% | 1,914,282 | 0.0% | 1.06% | +60.7% |
Q3 2018 | $54,844,000 | – | 1,914,282 | – | 0.66% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Saturn V Capital Management LP | 1,126,579 | $33,504,459 | 14.02% |
New Leaf Venture Partners, L.L.C. | 141,000 | $4,193,340 | 5.38% |
First Light Asset Management, LLC | 1,583,329 | $47,088,204 | 4.47% |
Paradigm Biocapital Advisors LP | 2,178,737 | $64,795,638 | 4.40% |
Bain Capital Life Sciences Investors, LLC | 1,275,552 | $37,934,916 | 4.24% |
Altium Capital Management LP | 262,000 | $7,791,880 | 4.06% |
5AM Venture Management, LLC | 462,286 | $13,748,386 | 3.96% |
MPM BioImpact LLC | 479,053 | $14,247,036 | 3.80% |
Affinity Asset Advisors, LLC | 450,000 | $13,383,000 | 3.76% |
Opaleye Management Inc. | 370,000 | $11,003,800 | 3.58% |